RxDoctor Payments Data

Allison Burton, MD

Family Medicine · Wesley Chapel, FLNPI 1902004831

Payments from drug & device makers

$6,870in general payments, 2019–2025

Across 383 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$809
  • AstraZeneca$621
  • Pfizer$571
  • Lilly USA, LLC$314
  • GSK$298
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,842100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,870 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$76,946
Medicare patients
285
Services billed
855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$54,682
EliquisApixaban23$29,295
JardianceEmpagliflozin14$24,885
JanumetSitagliptin Phos/Metformin Hcl17$21,835
XareltoRivaroxaban20$16,746
Breo ElliptaFluticasone/Vilanterol15$13,964
JanuviaSitagliptin Phosphate11$13,814
LinzessLinaclotide15$9,272
SynthroidLevothyroxine Sodium72$5,480
Bupropion XlBupropion Hcl22$3,846
Levothyroxine Sodium452$3,675
Atorvastatin Calcium462$3,654
Rosuvastatin Calcium389$2,646
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$2,519
Gabapentin232$2,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,327$54,68247 claims
MerckJanumet, Januvia$100$35,64928 claims
PfizerEliquis$571$29,29523 claims
Boehringer IngelheimJardiance$189$24,88514 claims
Johnson & JohnsonXarelto$95$16,74620 claims
AbbVieLinzess, Synthroid$809$14,75287 claims
GSKBreo Ellipta$298$13,96415 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$90$89011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →